Skip to main content
Fig. 1 | Lipids in Health and Disease

Fig. 1

From: Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

Fig. 1

Top Panel: Total, direct, and indirect costs, expected CVD costs for the next 10 years, and loss of present value of lifetime earnings (PVLE), and costs of PCSK9 inhibitor therapy in 61 hypercholesterolemic patients who had sustained a cardiovascular event (CVD) in the past 10 ± 9 years. Bottom Panel: Assume PCSK9 inhibitor therapy was used and reduced CVD events by 50 % and lowered PVLE loss

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X